Merck responds to Arcoxia approvable letter

Share this content:
Merck has responded to an FDA “approvable” letter for Arcoxia (etoricoxib), an investigational selective Cox-2 inhibitor, with results of the MEDAL program. The company is hoping Arcoxia can take the place of Vioxx.

Share this content:
Scroll down to see the next article